Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …

Drug delivery systems (DDS) are defined as methods by which drugs are delivered to
desired tissues, organs, cells and subcellular organs for drug release and absorption …

Increasing attention has been paid to the diseases of central nervous system (CNS). The
penetration efficiency of most CNS drugs into the brain parenchyma is rather limited due to …

The blood brain barrier (BBB) presents a formidable challenge to the delivery of drugs into
the brain. Several strategies aim to overcome this obstacle and promote efficient and …

Nanomaterial-based drug delivery systems (NBDDS) are widely used to improve the safety
and therapeutic efficacy of encapsulated drugs due to their unique physicochemical and …

Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although
poor delivery to the brain hinders their therapeutic application. In the current study, it is …

Recent advances in technology are expected to increase our current understanding of
neuroscience. Nanotechnology and nanomaterials can alter and control neural functionality …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Effective treatments of neurodegenerative diseases require drugs to be actively transported
across the blood-brain barrier (BBB). However, nanoparticle drug carriers explored for this …